





COMPOUND

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-((1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-N-2-propyn-1-yl-2-thiazolamine

PubChem CID	5282340
Structure	<div></div> <div>2D3D</div>
Molecular Formula	C ₂₇ H ₂₈ ClFN ₂ OS
Synonyms	Crinecerfont 752253-39-7 SSR 125543 SSR-125543 Crenessity View More...
Molecular Weight	483.0 g/mol <small>Computed by PubChem 2.2 (PubChem release 2025.04.14)</small>
Dates	Create: 2005-10-11 Modify: 2026-05-23
Description	<p>SSR 125543 is an amine.</p> <p>ChEBI</p> <p>Patients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory overproduction of adrenocorticotrophic hormone (ACTH) from the pituitary. Standard therapy involves cortisol replacement, but typically requires supraphysiological glucocorticoid doses to lower both ACTH and adrenal androgens, resulting in chronic glucocorticoid overexposure. The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently attenuate excessive androgen production. Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary. When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated with glucocorticoid overexposure. Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.</p> <p>DrugBank</p>

Cite

Download

CONTENTS

Title and Summary

1 Structures

2 Names and Identifiers

3 Chemical and Physical Properties

4 Related Records

5 Chemical Vendors

6 Drug and Medication Information

7 Pharmacology and Biochemistry

8 Toxicity

9 Associated Disorders and Diseases

10 Literature

11 Patents

12 Interactions and Pathways

13 Biological Test Results

14 Classification

15 Information Sources

Crinecerfont is a Corticotropin-releasing Factor Type 1 Receptor Antagonist. The mechanism of action of crinecerfont is as a Corticotropin-releasing Factor Type 1 Receptor Antagonist.

► [FDA Pharm Classes](#)

Crinecerfont is small molecule inhibitor of the corticotropin releasing factor receptor which is used to treat patients with congenital adrenal hyperplasia. Crinecerfont is has not been associated with significant elevations in serum aminotransferase levels during therapy or with instances of clinically apparent liver injury.


► [LiverTox](#)

[View Less...](#)


1 Structures



1.1 2D Structure



1.2 3D Conformer



2 Names and Identifiers



2.1 Computed Descriptors



2.1.1 IUPAC Name



4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine

Computed by Lexichem TK 2.7.0 (PubChem release 2025.04.14)

[PubChem](#)

2.1.2 InChI



InChI=1S/C₂₇H₂₈ClFN₂OS/c1-6-11-31(24(13-19-8-9-19)20-10-7-16(2)23(29)14-20)27-30-26(18(4)33-27)21-12-17(3)25(32-5)15-22(21)28/h1,7,10,12,14-15,19,24H,8-9,11,13H,2,2-5H3/t24-/m0/s1

Computed by InChI 1.07.2 (PubChem release 2025.04.14)

[PubChem](#)

2.1.3 InChIKey



IEAKXXNRGSLYTQ-DEOSSOPVSA-N

Computed by InChI 1.07.2 (PubChem release 2025.04.14)

[PubChem](#)

2.1.4 SMILES



CC1=C(C=C(C=C1))[C@H](CC2CC2)N(CC#C)C3=NC(=C(S3)C)C4=C(C=C(C(=C4)C)OC)Cl)F

Computed by OEChem 2.3.0 (PubChem release 2025.04.14)

[PubChem](#)

2.2 Molecular Formula



C₂₇H₂₈ClFN₂OS

Computed by PubChem 2.2 (PubChem release 2025.04.14)

[PubChem](#)

2.3 Other Identifiers



2.3.1 CAS



752253-39-7

[CAS Common Chemistry](#); [ChemIDplus](#); [DrugBank](#); [EPA DSSTox](#); [FDA Global Substance Registration System \(GSRS\)](#)

2.3.2 UNII



MFT24BX55I

[FDA Global Substance Registration System \(GSRS\)](#)

2.3.3 ChEBI ID



ChEBI:34969

[ChEBI](#)

2.3.4 ChEMBL ID



ChEMBL1628268

[ChEMBL](#)

ChEMBL291657

[ChEMBL](#); [Open Targets](#)

2.3.5 DrugBank ID



DB18518

▶ DrugBank

2.3.6 DSSTox Substance ID



DTXSID10996687

▶ EPA DSSTox

2.3.7 International Nonproprietary Names (INN)



CRINECERFONT

▶ FDA Global Substance Registration System (GSRS)

2.3.8 KEGG ID



D12366

▶ KEGG

2.3.9 NCI Thesaurus Code



C174708

▶ NCI Thesaurus (NCIt)

2.3.10 Nikkaji Number



J2.788.046K

▶ Japan Chemical Substance Dictionary (Nikkaji)

2.3.11 Pharos Ligand ID



W3JYT8TJURTS

▶ Pharos

2.3.12 RXCUI



2701386

▶ NLM RxNorm Terminology

2.3.13 United States Adopted Name (USAN)



CRINECERFONT

▶ FDA Global Substance Registration System (GSRS)

2.3.14 Wikidata



Q27088874

▶ Wikidata

2.3.15 Wikipedia



Crinecerfont

▶ Wikipedia

2.4 Synonyms

2.4.1 MeSH Entry Terms

crinecerfont

4-(2-chloro-4-methoxy-5-methylphenyl)-N-((1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine

NBI-74788

NBI 74788

Crenessity

SSR-125543

Medical Subject Headings (MeSH)

2.4.2 Depositor-Supplied Synonyms

Crinecerfont

752253-39-7

SSR 125543

SSR-125543

Crenessity

06-RORI

Nbi-74788

MFT24BX55I

4-(2-chloro-4-methoxy-5-methylphenyl)-N-((1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine

PubChem

3 Chemical and Physical Properties

3.1 Computed Properties

Property Name	Property Value	Reference
Molecular Weight	483.0 g/mol	Computed by PubChem 2.2 (PubChem release 2025.04.14)
XLogP3-AA	8	Computed by XLogP3 3.0 (PubChem release 2025.04.14)
Hydrogen Bond Donor Count	0	Computed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)
Hydrogen Bond Acceptor Count	5	Computed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)
Rotatable Bond Count	8	Computed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)
Exact Mass	482.1594906 Da	Computed by PubChem 2.2 (PubChem release 2025.04.14)
Monoisotopic Mass	482.1594906 Da	Computed by PubChem 2.2 (PubChem release 2025.04.14)
Topological Polar Surface Area	53.6 Å²	Computed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)
Heavy Atom Count	33	Computed by PubChem
Formal Charge	0	Computed by PubChem
Complexity	699	Computed by Cactvs 3.4.8.18 (PubChem release 2025.04.14)
Isotope Atom Count	0	Computed by PubChem
Defined Atom Stereocenter Count	1	Computed by PubChem
Undefined Atom Stereocenter Count	0	Computed by PubChem

Defined Bond Stereocenter Count	0	Computed by PubChem
Undefined Bond Stereocenter Count	0	Computed by PubChem
Covalently-Bonded Unit Count	1	Computed by PubChem
Compound Is Canonicalized	Yes	Computed by PubChem (release 2025.04.14)

► [PubChem](#)

3.2 Chemical Classes



3.2.1 Drugs



3.2.1.1 Human Drugs



Breast Feeding; Lactation; Milk, Human

► [Drugs and Lactation Database \(LactMed\)](#)

FDA approved drugs -> Active ingredient

► [Drugs@FDA; FDA Orange Book](#)

4 Related Records



4.1 Related Compounds with Annotation



Follow these links to [do a live 2D search](#) or [do a live 3D search](#) for this compound, sorted by annotation score. This section is deprecated (see [the neighbor discontinuation help page](#) for details), but these live search links provide equivalent functionality to the table that was previously shown here.

► [PubChem](#)

4.2 Related Compounds



Same Connectivity Count	7
Same Stereo Count	4
Same Isotope Count	3
Same Parent, Connectivity Count	11
Same Parent, Stereo Count	6
Same Parent, Isotope Count	7
Same Parent, Exact Count	3
Mixtures, Components, and Neutralized Forms Count	6
Similar Compounds (2D)	View in PubChem Search
Similar Conformers (3D)	View in PubChem Search

► [PubChem](#)

4.3 Substances



4.3.1 PubChem Reference Collection SID



505575159

► [PubChem](#)

4.3.2 Related Substances



All Count	138
Same Count	75
Mixture Count	63

[► PubChem](#)

4.3.3 Substances by Category



8 categories	Download
Chemical Vendors (37)	
AiFCHEM, an XtalPi Company	
PubChem SID: 508293103	External ID: ACLGHT628
BenchChem	
PubChem SID: 446438046	External ID: B1669616
Excenen Pharmatech	
PubChem SID: 518521065	External ID: EX-A15497
10X CHEM	
PubChem SID: 491552545	External ID: TX005NYP
Debye Scientific Co., Ltd	
PubChem SID: 496741488	External ID: DA-78023
BLD Pharm	
PubChem SID: 523965638	External ID: BD01394007
MedChemexpress MCE	
PubChem SID: 461503573	External ID: HY-106203
TargetMol	
PubChem SID: 494448094	External ID: T31095
BOC Sciences	
PubChem SID: 441158728	External ID: 752253-39-7
AstaTech, Inc.	
PubChem SID: 505061391	External ID: AT46091
AbaChemScene	
PubChem SID: 463561210	External ID: CS-0025238
Biorbyt	
PubChem SID: 516431582	External ID: orb1304529
PubChem SID: 522838932	External ID: orb3033028
Mcule	
PubChem SID: 493553177	External ID: MCULE-5744636773
PubChem SID: 494193126	External ID: MCULE-6859372505
J&H Chemical Co.,Ltd	
PubChem SID: 469608935	External ID: JH469047
Win-Win Chemical	
PubChem SID: 496163285	External ID: 38507
eMolecules	
PubChem SID: 490801745	External ID: 301245448
AKos Consulting & Solutions	
PubChem SID: 481563851	External ID: AKOS040751318
Accel Scientific	
PubChem SID: 507616692	External ID: EC005OYJ
eNovation Chemicals	
PubChem SID: 508701786	External ID: Y3306124
A2B Chem	
PubChem SID: 480588866	External ID: AC62627
Angene Chemical	
PubChem SID: 521979837	External ID: AG005MSR

SynHet - Synthetic Heterocycles	
PubChem SID: 505982300	External ID: CAS-752253-39-7
DempoChem	
PubChem SID: 518032096	External ID: 752253-39-7
Protheragen	
PubChem SID: 521257007	External ID: API0232752
Starshine Chemical	
PubChem SID: 480486690	External ID: 2023-05-7C02919
Smolecule	
PubChem SID: 438454854	External ID: 5524452
AA BLOCKS	
PubChem SID: 479914414	External ID: AA005MPZ
RR Scientific	
PubChem SID: 481391142	External ID: R746744
EvitaChem	
PubChem SID: 485958977	External ID: evt-265434
Alfa Chemistry	
PubChem SID: 527985301	External ID: CCR752253397
AChemBlock	
PubChem SID: 523550306	External ID: Y227829
Enamine	
PubChem SID: 521600486	External ID: EBC-2611075
Key Organics/BIONET	
PubChem SID: 486525901	External ID: TS-08701
001Chemical	
PubChem SID: 440048050	External ID: DY570262
InvivoChem	
PubChem SID: 500196892	External ID: V18805
Curation Efforts (15)	
BindingDB (Curation Efforts, Research and Development)	
PubChem SID: 104033304	External ID: 50144192
PubChem SID: 136355514	External ID: 50348828
ChEBI (Curation Efforts, Research and Development)	
PubChem SID: 223442240	External ID: CHEBI:34969
ChEMBL (Curation Efforts, Research and Development)	
PubChem SID: 103258755	External ID: ChEMBL291657
ChemIDplus (Curation Efforts, Governmental Organizations, Research and Development)	
PubChem SID: 135332214	External ID: 0752253397
Comparative Toxicogenomics Database (CTD) (Curation Efforts, Research and Development)	
PubChem SID: 163679273	External ID: C451725
Egon Willighagen, Department of Bioinformatics - BiGCaT, Maastricht University	
PubChem SID: 385653530	External ID: Q27088874
EPA DSSTox (Curation Efforts, Governmental Organizations, Research and Development)	
PubChem SID: 384553655	External ID: DTXSID10996687
FDA Global Substance Registration System (GSRS) (Curation Efforts, Governmental Organizations)	
PubChem SID: 317228876	External ID: MFT248X5SI
IUPHAR/BPS Guide to PHARMACOLOGY (Curation Efforts, Research and Development)	
PubChem SID: 178100512	External ID: 3533
KEGG (Curation Efforts, Research and Development)	
PubChem SID: 497620779	External ID: D12366
SureChEMBL (Curation Efforts, Research and Development)	
PubChem SID: 514292025	External ID: SCHEMBL29482256
PubChem SID: 231281768	External ID: SCHEMBL5453205
Therapeutic Target Database (TTD) (Curation Efforts, Research and Development)	
PubChem SID: 349979576	External ID: D05IIN
Wikidata	
PubChem SID: 386489988	External ID: Q27088874

Governmental Organizations (7)	
ChemIDplus (Curation Efforts, Governmental Organizations, Research and Development)	
PubChem SID: 135332214	External ID: 0752253397
EPA DSSTox (Curation Efforts, Governmental Organizations, Research and Development)	
PubChem SID: 384553655	External ID: DTXSID10996687
FDA Global Substance Registration System (GSRs) (Curation Efforts, Governmental Organizations)	
PubChem SID: 317228876	External ID: MFT24BX55I
Japan Chemical Substance Dictionary (Nikkaji)	
PubChem SID: 275503592	External ID: J2.788.046K
National Center for Advancing Translational Sciences (NCATS) (Governmental Organizations, NIH Initiatives)	
PubChem SID: 363680369	External ID: NCGC00386642-01
PATENTSCOPE (WIPO)	
PubChem SID: 389857487	External ID: IEAKXXNRGSLYTQ-DEOSSOPVSA-N
PubChem Reference Collection	
PubChem SID: 505575159	External ID: 579430
Journal Publishers (2)	
Springer Nature	
PubChem SID: 341196272	External ID: 33059069-373786447
Thieme Chemistry (Journal Publishers, Subscription Services)	
PubChem SID: 523047658	External ID: IEAKXXNRGSLYTQ-FQKVKQEKNA-N
NIH Initiatives (1)	
National Center for Advancing Translational Sciences (NCATS) (Governmental Organizations, NIH Initiatives)	
PubChem SID: 363680369	External ID: NCGC00386642-01
Research and Development (17)	
Ace Therapeutics	
PubChem SID: 491486508	External ID: SMD173
BindingDB (Curation Efforts, Research and Development)	
PubChem SID: 104033304	External ID: 50144192
PubChem SID: 136355514	External ID: 50348828
ChEBI (Curation Efforts, Research and Development)	
PubChem SID: 223442240	External ID: CHEBI:34969
ChEMBL (Curation Efforts, Research and Development)	
PubChem SID: 103258755	External ID: ChEMBL291657
ChemIDplus (Curation Efforts, Governmental Organizations, Research and Development)	
PubChem SID: 135332214	External ID: 0752253397
Comparative Toxicogenomics Database (CTD) (Curation Efforts, Research and Development)	
PubChem SID: 163679273	External ID: C451725
EPA DSSTox (Curation Efforts, Governmental Organizations, Research and Development)	
PubChem SID: 384553655	External ID: DTXSID10996687
Google Patents	
PubChem SID: 409337739	External ID: 2034967
IBM	
PubChem SID: 247029042	External ID: A68024F4BB23F5193569CD20C4E153AC
IUPHAR/BPS Guide to PHARMACOLOGY (Curation Efforts, Research and Development)	
PubChem SID: 178100512	External ID: 3533
KEGG (Curation Efforts, Research and Development)	
PubChem SID: 497620779	External ID: D12366
MolGenie	
PubChem SID: 500850489	External ID: 190002621616
Probes & Drugs portal	
PubChem SID: 482131550	External ID: PD051107
SureChEMBL (Curation Efforts, Research and Development)	
PubChem SID: 514292025	External ID: SCHEMBL29482256
PubChem SID: 231281768	External ID: SCHEMBL5453205

Therapeutic Target Database (TTD) (Curation Efforts, Research and Development)	
PubChem SID: 349979576	External ID: D05IIN
Subscription Services (1)	
Thieme Chemistry (Journal Publishers, Subscription Services)	
PubChem SID: 523047658	External ID: IEAKXXNRGSLYTQ-FQKVQKEKNA-N
Legacy Depositors (12)	
ABI Chem (Chemical Vendors)	
PubChem SID: 113856996	External ID: AC1NQZWP
Amadis Chemical (Chemical Vendors)	
PubChem SID: 498216771	External ID: A1241944
ChemBank (Research and Development)	
PubChem SID: 47954466	External ID: PDSP1_000883
PubChem SID: 48404470	External ID: PDSP2_000869
ChemSpider (Research and Development)	
PubChem SID: 39315801	External ID: 4445507
ChemTik (Chemical Vendors)	
PubChem SID: 162657196	External ID: CTK2H9991
DiscoveryGate (Subscription Services)	
PubChem SID: 8617013	External ID: 5282340
NextBio (Subscription Services)	
PubChem SID: 80608165	External ID: 5282340
NovoSeek (Chemical Vendors)	
PubChem SID: 57358622	External ID: 5282340
THE BioTek (Chemical Vendors)	
PubChem SID: 434249251	External ID: bt-265434
ToxPlanet (Subscription Services)	
PubChem SID: 319296398	External ID: ToxPlanet-NzUyMjUzLTU5LTc1MjgyMzQw
ZINC (Chemical Vendors)	
PubChem SID: 256203111	External ID: ZINC1550164

► PubChem

4.4 Entrez Crosslinks



PubMed Count	6
Gene Count	1

► PubChem

4.5 NCBI LinkOut



Provider	Information
Ingenuity Pathways Analysis	Chemical Information: molecular interactions

► NCBI

5 Chemical Vendors



35 vendors		Download
AiFCChem, an XtalPi Company	PubChem SID: 508293103	Purchasable Chemical: ACLGHT628
BenchChem	PubChem SID: 446438046	Purchasable Chemical: B1669616
Excenen Pharmatech	PubChem SID: 518521065	Purchasable Chemical: EX-A15497
10X CHEM	PubChem SID: 491552545	Purchasable Chemical: TX005NYF
Debye Scientific Co., Ltd	PubChem SID: 496741488	Purchasable Chemical: DA-78023
BLD Pharm	PubChem SID: 523965638	Purchasable Chemical: BD01394007
MedChemexpress MCE	PubChem SID: 461503573	Purchasable Chemical: HY-106203
TargetMol	PubChem SID: 494448094	Purchasable Chemical: T31095
BOC Sciences	PubChem SID: 441158728	Purchasable Chemical: 752253-39-7
AstaTech, Inc.	PubChem SID: 505061391	Purchasable Chemical: AT46091
AbaChemScene	PubChem SID: 463561210	Purchasable Chemical: CS-0025238
Biorbyt	PubChem SID: 516431582	Purchasable Chemical: orb1304529
	PubChem SID: 522838932	Purchasable Chemical: orb3033028
Mcule	PubChem SID: 493553177	Purchasable Chemical: MCULE-5744636773
	PubChem SID: 494193126	Purchasable Chemical: MCULE-6859372505
J&H Chemical Co.,Ltd	PubChem SID: 469608935	Purchasable Chemical: JH469047
Win-Win Chemical	PubChem SID: 496163285	Purchasable Chemical: 38507
eMolecules	PubChem SID: 490801745	Purchasable Chemical: 301245448
AKos Consulting & Solutions	PubChem SID: 481563851	Purchasable Chemical: AKOS040751318
Accel Scientific	PubChem SID: 507616692	Purchasable Chemical: EC005OYJ
eNovation Chemicals	PubChem SID: 508701786	Purchasable Chemical: Y3306124
A2B Chem	PubChem SID: 480588866	Purchasable Chemical: AC62627
Angene Chemical	PubChem SID: 521979837	Purchasable Chemical: AG005MSR
SynHet - Synthetic Heterocycles	PubChem SID: 505982300	Purchasable Chemical: CAS-752253-39-7
DempoChem	PubChem SID: 518032096	Purchasable Chemical: 752253-39-7
Protheragen	PubChem SID: 521257007	Purchasable Chemical: API0232752
Starshine Chemical	PubChem SID: 480486690	Purchasable Chemical: 2023-05-7C02919
Smolcule	PubChem SID: 438454854	Purchasable Chemical: S524452

AA BLOCKS	PubChem SID: 479914414	Purchasable Chemical: AA005MPZ
RR Scientific	PubChem SID: 481391142	Purchasable Chemical: R746744
EvitaChem	PubChem SID: 485958977	Purchasable Chemical: evt-265434
Alfa Chemistry	PubChem SID: 527985301	Purchasable Chemical: CCR752253397
AChemBlock	PubChem SID: 523550306	Purchasable Chemical: Y227829
Enamine	PubChem SID: 521600486	Purchasable Chemical: EBC-2611075
Key Organics/BIONET	PubChem SID: 486525901	Purchasable Chemical: TS-08701
001Chemical	PubChem SID: 440048050	Purchasable Chemical: DY570262
InvivoChem	PubChem SID: 500196892	Purchasable Chemical: V18805

► [PubChem](#)

6 Drug and Medication Information



6.1 Drug Indication



2 items		Download
MeSH Heading	EFO Term	Max Phase
Adrenal Hyperplasia, Congenital	congenital adrenal hyperplasia	Approved
Depressive Disorder	depressive disorder	Phase 2

► [ChEMBL](#)

Crinecerfont is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients ≥4 years of age with classic congenital adrenal hyperplasia (CAH).

► [DrugBank](#)

6.2 LiverTox Summary



Crinecerfont is small molecule inhibitor of the corticotropin releasing factor receptor which is used to treat patients with congenital adrenal hyperplasia. Crinecerfont is has not been associated with significant elevations in serum aminotransferase levels during therapy or with instances of clinically apparent liver injury.

► [LiverTox](#)

6.3 Drug Classes



Breast Feeding; Lactation; Milk, Human

► [Drugs and Lactation Database \(LactMed\)](#)

Genetic Disorder Agents

► [LiverTox](#)

6.4 FDA Approved Drugs

4 items  Download

Drug	Ingredient(s)	Dosage Form/Route	Strength	Marketing Status	Company	Application Number	Product Number
CRENESSITY	CRINECERFONT	CAPSULE;ORAL	25MG	Prescription	NEUROCRINE	218808	001
CRENESSITY	CRINECERFONT	CAPSULE;ORAL	50MG	Prescription	NEUROCRINE	218808	002
CRENESSITY	CRINECERFONT	CAPSULE;ORAL	100MG	Prescription	NEUROCRINE	218808	003
CRENESSITY	CRINECERFONT	SOLUTION;ORAL	50MG/ML	Prescription	NEUROCRINE	218820	001



[Drugs@FDA](#)

6.5 FDA Orange Book

4 items  Download

Trade Name	Application Number	Product Number	Applicant	Approval Date
CRENESSITY	218808	001	NEUROCRINE BIOSCIENCES INC	Dec 13, 2024
CRENESSITY	218808	002	NEUROCRINE BIOSCIENCES INC	Dec 13, 2024
CRENESSITY	218808	003	NEUROCRINE BIOSCIENCES INC	Dec 13, 2024
CRENESSITY	218820	001	NEUROCRINE BIOSCIENCES INC	Dec 13, 2024

[FDA Orange Book](#)

6.6 FDA National Drug Code Directory

4 items  Download

Product NDC	Start Marketing Date	Dosage Form	Strength	Labeler
70370-5025	2024-12-13	CAPSULE	25 mg/1	Neurocrine Biosciences, Inc.
70370-5050	2024-12-13	CAPSULE	50 mg/1	Neurocrine Biosciences, Inc.
70370-5100	2024-12-13	CAPSULE	100 mg/1	Neurocrine Biosciences, Inc.
70370-5250	2024-12-13	SOLUTION	50 mg/mL	Neurocrine Biosciences, Inc.

[National Drug Code \(NDC\) Directory](#)

6.7 Clinical Trials

6.7.1 ClinicalTrials.gov



7 items	Download
<input type="text" value="Search"/>	SORT BY Date - Most Recent
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia CTID: NCT04490915 Phase: Phase 3 Status: Active, not recruiting Date: 2026-05-11	
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old CTID: NCT07536269 Phase: Phase 2 Status: Not yet recruiting Date: 2026-04-17	
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old CTID: NCT07187375 Phase: Phase 2 Status: Recruiting Date: 2026-03-20	
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyt Pediatric Study) CTID: NCT04806451 Phase: Phase 3 Status: Active, not recruiting Date: 2025-02-05	
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia CTID: NCT04045145 Phase: Phase 2 Status: Completed Date: 2024-07-18	
<< First < Previous Page 1 of 2 Next > Last >>	

► [ClinicalTrials.gov](#)

6.7.2 EU Clinical Trials Register



3 items	Download
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment EudraCT: 2020-004381-19 Phase: Phase 3 Status: Trial now transitioned, Ongoing Date: 2021-06-07	
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment EudraCT: 2019-004873-17 Phase: Phase 3 Status: Trial now transitioned, GB - no longer in EU/EEA, Ongoing Date: 2020-10-15	
An eight-week, multinational, multicenter, double-blind, active- and placebo-controlled clinical trial evaluating the efficacy and tolerability of three fixed doses of SSR125543 (20 mg daily, 50 mg daily and 100 mg daily) in outpatients with major depressive disorder. EudraCT: 2009-010339-42 Phase: Phase 2 Status: Completed Date: 2010-02-10	

▶ [EU Clinical Trials Register](#)

6.8 EMA Drug Information

2 items	 Download
Category/Dataset: Paediatric investigation plans (PIP)	
Product/no.: PIP number: EMEA-002700-PIP01-19-M02 Active Substance: crinecerfont	
Status: PIP decision type: PM: decision on the application for modification of an agreed PIP	
Pharmaceutical Form: Capsule, hard;Oral solution Administration Route: Oral use;Gastric use	
Therapeutic Use: Congenital, familial and genetic disorders	
Condition/Indication: Treatment of congenital adrenal hyperplasia	
Publish Date: 2024-06-14 Update Date: 2025-07-07	
Category/Dataset: Paediatric investigation plans (PIP)	
Product/no.: PIP number: EMEA-002700-PIP01-19 Active Substance: crinecerfont	
Status: PIP decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)	
Pharmaceutical Form: Capsule, hard;Oral solution Administration Route: Subcutaneous use;Intravenous use	
Therapeutic Use: Endocrinology-Gynaecology-Fertility-Metabolism	
Condition/Indication: Treatment of atypical haemolytic uremic syndrome;Treatment of paroxysmal nocturnal haemoglobinuria	
Publish Date: 2021-03-17	

▶ [European Medicines Agency \(EMA\)](#)

6.9 Drug Development Summary

Max Phase	Approved
First Approval	2024
Availability Type	Prescription Only
Route of Administration	Oral

▶ [ChEMBL](#)

6.10 Drug Targets

3 items	 Download		
Structure	Gene	Protein	Open Targets Target ID
	CRHR1	corticotropin releasing hormone receptor 1	ENSG00000120088
	CRHR1	corticotropin releasing hormone receptor 1	ENSG00000120088
	CRHR1	corticotropin releasing hormone receptor 1	ENSG00000120088

▶ [Open Targets](#)

6.11 Drug-Food Interactions

Take with food. Overall exposure to crinecerfont is increased when it is administered with a meal.

[DrugBank](#)

7 Pharmacology and Biochemistry



7.1 Pharmacodynamics



In eight adult patients with CAH administered the recommended dosage of crinecerfont for two weeks, the median percent reduction from baseline in ACTH was 62%. In the Phase 3 clinical trials of adults and pediatric patients with classic CAH, administration of the recommended crinecerfont dosage for 4 weeks during the initial glucocorticoid stable period led to a reduction in ACTH levels of 65% in one study and 72% in the other. Patients undergoing treatment with crinecerfont must continue concomitant glucocorticoid replacement therapy. Doses should be maintained at (or above) the dose required for [cortisol](#) replacement. Any dose adjustments should be performed under the supervision of a health care provider.

[DrugBank](#)

7.2 FDA Pharmacological Classification



FDA UNII	MFT248X55I
Active Moiety	CRINECERFONT
Pharmacological Classes	Established Pharmacologic Class (EPC) - Corticotropin-releasing Factor Type 1 Receptor Antagonist
Pharmacological Classes	Mechanisms of Action [MoA] - Corticotropin-releasing Factor Type 1 Receptor Antagonists
FDA Pharmacology Summary	Crinecerfont is a Corticotropin-releasing Factor Type 1 Receptor Antagonist. The mechanism of action of crinecerfont is as a Corticotropin-releasing Factor Type 1 Receptor Antagonist.

[FDA Pharm Classes](#)

7.3 Absorption, Distribution and Excretion



Absorption

In adult patients at steady-state, the AUC_{0-24h} and C_{max} of crinecerfont were 72846 ng*h/mL and 4231 ng/mL, respectively. In pediatric patients at steady-state, the AUC_{0-24h} ranged from 47062 to 74693 ng*h/mL and the C_{max} ranged from 2887 to 4555 ng/mL, depending on the administered dose. The median time to C_{max} (i.e. T_{max}) is four hours.

[DrugBank](#)

Route of Elimination

Following a single oral 100 mg dose of radiolabeled crinecerfont, approximately 47.3% of the dose was recovered in feces (2.7% as unchanged parent drug) and 2% in urine (undetectable levels of unchanged parent drug).

[DrugBank](#)

Volume of Distribution

The mean apparent volume of distribution of crinecerfont in adults is 852 liters.

[DrugBank](#)

Clearance

The apparent clearance of crinecerfont is 3.5 L/h.

[DrugBank](#)

7.4 Protein Binding



Crinecerfont is highly (≥99.9%) protein bound in plasma.

[DrugBank](#)

7.5 Metabolism / Metabolites



In vitro, crinecerfont is primarily metabolized by CYP3A4 and to a lesser extent CYP2B6. Additionally, CYP2C8 and CYP2C19 may also have minor contributions to crinecerfont metabolism.

► [DrugBank](#)

7.6 Biological Half-Life



The effective half-life of crinecerfont is approximately 14 hours.

► [DrugBank](#)

7.7 Mechanism of Action



Crinecerfont exerts its therapeutics effects via selective antagonism of corticotropin releasing factor (CRF) type 1 receptor, which is abundant in the pituitary gland. It blocks the binding of CRF to CRF type 1 receptors in the pituitary gland, which inhibits the secretion of adrenocorticotrophic hormone (ACTH) from the pituitary. This reduction in ACTH leads to decreased adrenal androgen production and lower levels of steroid precursors, such as 17OH-[progesterone](#).

► [DrugBank](#)

8 Toxicity



8.1 Toxicological Information



8.1.1 Hepatotoxicity



In registration clinical trials, liver test abnormalities were infrequent during crinecerfont therapy and no more common than with placebo. There were no instances of ALT or AST elevations above 3 times the upper limit of normal (ULN) and no cases of liver injury with jaundice or symptoms. Clinical experience with crinecerfont therapy has been limited, but there have no published reports of clinical apparent liver injury with its use.

Likelihood score: E (unlikely cause of clinically apparent liver injury).

► [LiverTox](#)

8.1.2 Effects During Pregnancy and Lactation



● Summary of Use during Lactation

No information is available on the use of crinecerfont during breastfeeding. Because crinecerfont is more than 99% bound to plasma proteins, amounts in milk are likely to be low. If a mother requires crinecerfont, it is not a reason to discontinue breastfeeding. Breastfed infants should be monitored for signs of adrenal insufficiency such as weakness, decreased feeding and weight loss.

● Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

● Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

► [Drugs and Lactation Database \(LactMed\)](#)

9 Associated Disorders and Diseases



2 items Download	
Source Disease	Data Source
Adrenal Hyperplasia, Congenital	ChEMBL
Depressive Disorder	ChEMBL

► [Therapeutic Target Database \(TTD\)](#)

10 Literature



10.1 Consolidated References



36 items

Download

SORT BY Publication Date - Most Recent

Crinecerfont

Publication Name: Pharmaceutical Substances

Publication Date: 2026

Crinecerfont: First Approval

Publication Name: Drugs

Publication Date: 2025-04-17

PMID: 40240539 DOI: 10.1007/s40265-025-02165-1

Dissecting the Relationship Between Neuropsychiatric and Neurodegenerative Disorders

Publication Name: Molecular Neurobiology

Publication Date: 2023-07-17

PMID: 37458987 DOI: 10.1007/s12035-023-03502-9

Target Class Profiling of Small-Molecule Methyltransferases

Publication Name: ACS Chemical Biology

Publication Date: 2023-03-28

PMCID: PMC10983791 PMID: 36976909 DOI: 10.1021/acscchembio.3c00124

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia

Publication Name: The Journal of clinical endocrinology and metabolism

Publication Date: 2021-10-15

PMCID: PMC8851935 PMID: 34653252 DOI: 10.1210/clinem/dgab749

<< First < Previous Page 1 of 8 Next > Last >>

PubChem

10.2 NLM Curated PubMed Citations



All NLM Curated PubMed Citations

Download


Medical Subject Headings (MeSH)

10.3 Springer Nature References



23 items Download

Search SORT BY Publication Date - Oldest

	<p>Selectively Bred Rodents as Models of Depression and Anxiety</p> <p>PMID: 22351423</p> <p>Publication Date: 2011</p> <p>Publication Name: Behavioral Neurogenetics</p>
	<p>Emerging novel treatments for severe mood disorders involving cellular plasticity cascades</p> <p>PMID: 25620894</p> <p>Publication Date: 2006</p> <p>Publication Name: Current Psychosis & Therapeutics Reports</p>
	<p>Effects of a stressor and corticotrophin releasing factor on ethanol deprivation-induced ethanol intake and anxiety-like behavior in alcohol-preferring P rats</p> <p>PMID: 21643675</p> <p>Publication Date: 2011</p> <p>Publication Name: Psychopharmacology</p>
	<p>Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression</p> <p>PMID: 26700241</p> <p>Publication Date: 2015</p> <p>Publication Name: Psychopharmacology</p>
	<p>Innovative approaches for the development of antidepressant drugs: Current and future strategies</p> <p>PMID: 16489368</p> <p>Publication Date: 2005</p> <p>Publication Name: NeuroRX</p>

« First < Previous Page 1 of 5 Next > Last »

► Springer Nature

10.4 Thieme References





1 item Download

<p>Crinecerfont</p> <p>Publication Date: 2026</p> <p>Publication Name: Pharmaceutical Substances</p>
--

► Thieme Chemistry

10.5 Chemical Co-Occurrences in Literature



Showing 3 of 100 View More Co-Occurrence and Evidence Data	
Chemical	Selected evidence
 Cortisol CID 5754	<p>21 articles View All </p> <p>Correction: CRF1 and ACTH inhibitors are a promising approach to treat obesity and leptin and insulin resistance PMID 41122708; DOI 10.3389/fendo.2025.1647028; Frontiers in Endocrinology 2025-10-06 Name matches: cortisol crinecerfont</p> <p>Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency PMID 39836617; DOI 10.1210/clinem/dgae759; The Journal of clinical endocrinology and metabolism 2025-01-21 (Review Article) Name matches: hydrocortisone crinecerfont</p> <p>[Endocrinology : what's new in 2024] PMID 39846096; DOI 10.53738/revmed.2025.21.902.126; Revue medicale suisse 2025-01-22 Name matches: cortisol crinecerfont</p>
 Corticorelin CID 16186200	<p>14 articles View All </p> <p>Effects of the CRF1 receptor antagonist SSR125543 on energy balance and food deprivation-induced neuronal activation in obese Zucker rats PMID 17400798; DOI 10.1677/joe.1.07064; The Journal of endocrinology 2007-04-01</p> <p>Control of Stress-Induced ACTH Secretion by Vasopressin and CRH: Additional Evidence PMID 27221315; DOI 10.1159/000445480; Neuropsychobiology 2016-01-01</p> <p>Corticolimbic Transcriptome Changes are State-Dependent and Region-Specific in a Rodent Model of Depression and of Antidepressant Reversal PMID 18536703; DOI 10.1038/npp.2008.76; Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008-06-04</p>
 Fluoxetine CID 3386	<p>13 articles View All </p> <p>Corticolimbic Transcriptome Changes are State-Dependent and Region-Specific in a Rodent Model of Depression and of Antidepressant Reversal PMID 18536703; DOI 10.1038/npp.2008.76; Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008-06-04 Name matches: fluoxetine ssr125543</p> <p>Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat PMID 16452986; DOI 10.1038/sj.npp.1301036; Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006-02-01 Name matches: fluoxetine ssr125543</p> <p>The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice PMID 21356230; DOI 10.1016/j.pbb.2011.02.019; Pharmacology, biochemistry, and behavior 2011-05-01 Name matches: fluoxetine ssr125543</p>

► PubChem

10.6 Chemical-Gene Co-Occurrences in Literature

Showing 3 of 86 [View More Co-Occurrence and Evidence Data](#)  Download

Gene/Protein/Enzyme	Selected evidence
corticotropin releasing hormone receptor 1	<div>26 articles View All </div> <div>The CRF1 receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: Comparison with paroxetine and d-cycloserine PMID 23446760; DOI 10.1016/j.bbr.2014.11.006; Behavioural Brain Research 2015-02-15</div> <div>The CRF1 receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and d-cycloserine PMID 23407783; DOI 10.1007/s00213-013-3020-1; Psychopharmacology 2013-02-14</div> <div>The CRF1 receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis PMID 22659580; DOI 10.1016/j.pbb.2012.05.013; Pharmacology, biochemistry, and behavior 2012-09-01</div>
corticotropin releasing hormone	<div>24 articles View All </div> <div>CRH receptor antagonist crinecerfont – a promising new treatment option for patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency PMID 39576723; DOI 10.1515/jpem-2024-0440; Journal of pediatric endocrinology & metabolism : JPEM 2024-11-25 Name matches: crh <i>crinecerfont</i></div> <div>Deep brain stimulation in treatment-resistant depression in mice: Comparison with the CRF1 antagonist, SSR125543 PMID 23367508; DOI 10.1016/j.pnpbp.2012.07.019; Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013-01-10</div> <div>Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter! PMID 37650613; DOI 10.1210/clinem/dgad513; The Journal of clinical endocrinology and metabolism 2023-08-31 Name matches: crh <i>crinecerfont</i></div>
proopiomelanocortin	<div>8 articles View All </div> <div>Crinecerfont: CRF1R Antagonist Approved for Treatment of Congenital Adrenal Hyperplasia PMID 41321281; DOI 10.1177/10600280251396594; The Annals of pharmacotherapy 2025-12-01 (Review Article)</div> <div>Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia PMID 37216921; DOI 10.1210/clinem/dgad270; The Journal of clinical endocrinology and metabolism 2023-05-22</div> <div>Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives PMID 41921547; DOI 10.1210/clinem/dgag147; The Journal of clinical endocrinology and metabolism 2026-04-01</div>

► PubChem

10.7 Chemical-Disease Co-Occurrences in Literature

Showing 3 of 81 View More Co-Occurrence and Evidence Data 		 Download
Disease	Selected evidence	
Adrenal Hyperplasia, Congenital	14 articles	View All 
	Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia PMID 38828955; DOI 10.1056/nejmoa2404656; The New England journal of medicine 2024-08-08 Name matches: cah ; congenital adrenal hyperplasia <i>crinecerfont</i>	
	Crinecerfont: CRF1R Antagonist Approved for Treatment of Congenital Adrenal Hyperplasia PMID 41321281; DOI 10.1177/10600280251396594; The Annals of pharmacotherapy 2025-12-01 (Review Article) Name matches: cah ; congenital adrenal hyperplasia <i>crinecerfont</i>	
Congenital adrenal hyperplasia due to 21 hydroxylase deficiency	8 articles	View All 
	Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia PMID 34653252; DOI 10.1210/clinem/dgab749; The Journal of clinical endocrinology and metabolism 2021-10-15 Name matches: 21-hydroxylase deficiency ; 21ohd <i>crinecerfont</i>	
	Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia PMID 37216921; DOI 10.1210/clinem/dgad270; The Journal of clinical endocrinology and metabolism 2023-05-22 Name matches: 21-hydroxylase deficiency ; 21ohd <i>crinecerfont</i>	
Anxiety Disorders	13 articles	View All 
	Cytokine involvement in stress may depend on corticotrophin releasing factor to sensitize ethanol withdrawal anxiety PMID 21377524; DOI 10.1016/j.bbi.2011.02.018; Brain, Behavior, and Immunity 2011-06-01 Name matches: anxiety <i>ssr125543</i>	
	Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects PMID 24569014; DOI 10.1016/j.bbr.2014.02.024; Behavioural Brain Research 2014-05-15 Name matches: anxiety <i>ssr125543</i>	
	Effects of a stressor and corticotrophin releasing factor on ethanol deprivation-induced ethanol intake and anxiety-like behavior in alcohol-preferring P rats PMID 21643675; DOI 10.1007/s00213-011-2366-5; Psychopharmacology 2011-06-04 Name matches: anxiety <i>ssr125543</i>	

 PubChem

10.8 Chemical-Organism Co-Occurrences in Literature



Showing 3 of 14 View More Co-Occurrence and Evidence Data

Download

Organism	Selected evidence
mus sp. (mice)	<p>13 articles View All </p> <p>The CRF1 receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis PMID 22659580; DOI 10.1016/j.pbb.2012.05.013; Pharmacology, biochemistry, and behavior 2012-09-01 Name matches: mice <i>ssr125543</i></p> <p>Deep brain stimulation in treatment-resistant depression in mice: Comparison with the CRF1 antagonist, SSR125543 PMID 23367508; DOI 10.1016/j.pnpbp.2012.07.019; Progress in Neuro-Psychopharmacology and Biological Psychiatry 2013-01-10 Name matches: mice <i>ssr125543</i></p> <p>The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice PMID 21356230; DOI 10.1016/j.pbb.2011.02.019; Pharmacology, biochemistry, and behavior 2011-05-01 Name matches: mice <i>ssr125543</i></p>
rattus sp. (rats)	<p>14 articles View All </p> <p>Effects of the vasopressin (V1B) receptor antagonist, SSR149415, and the corticotropin-releasing factor 1 receptor antagonist, SSR125543, on FG 7142-induced increase in acetylcholine and norepinephrine release in the rat PMID 16781820; DOI 10.1016/j.neuroscience.2006.05.006; Neuroscience 2006-09-01 Name matches: rat; rats <i>ssr125543</i></p> <p>Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat PMID 16452986; DOI 10.1038/sj.npp.1301036; Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006-02-01 Name matches: rat <i>ssr125543</i></p> <p>Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression PMID 15321734; DOI 10.1016/j.ejphar.2004.06.035; European Journal of Pharmacology 2004-08-16 Name matches: rat; rats <i>ssr125543</i></p>
metazoa (animals)	<p>10 articles View All </p> <p>Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression PMID 15321734; DOI 10.1016/j.ejphar.2004.06.035; European Journal of Pharmacology 2004-08-16 Name matches: animal <i>ssr125543</i></p> <p>The CRF1 receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis PMID 22659580; DOI 10.1016/j.pbb.2012.05.013; Pharmacology, biochemistry, and behavior 2012-09-01 Name matches: animal; animals <i>ssr125543</i></p> <p>Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat PMID 16452986; DOI 10.1038/sj.npp.1301036; Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006-02-01 Name matches: animal <i>ssr125543</i></p>

11 Patents



US12128033
 US10905690
 US11311544
 US11730739

► [DrugBank](#)

11.1 Depositor-Supplied Patent Identifiers



203 items		Download
Search	SORT BY	Priority Date - Most Recent
Tildacerfont cocrystal formulations		
Publication Number: WO-2024243431-A1		
Priority Date: 2023-05-24		
Dosage regime of crinecerfont for treating congenital adrenal hyperplasia in a pediatric subject		
Publication Number: WO-2024233525-A1		
Priority Date: 2023-05-08		
Methods for the administration of crf antagonist		
Publication Number: TW-202444356-A		
Priority Date: 2023-05-08		
Dosage regime of crinecerfont for treating congenital adrenal hyperplasia		
Publication Number: WO-2024206769-A1		
Priority Date: 2023-03-30		
Methods and bioavailable highly permeable compounds for diseases treatment		
Publication Number: WO-2024189607-A1		
Priority Date: 2023-03-16		
<< First < Previous Page 1 of 41 Next > Last >>		

► [PubChem](#)

[Link to all deposited patent identifiers](#)

► [PubChem](#)

11.2 WIPO PATENTSCOPE



Patents are available for this chemical structure:

<https://patentscope.wipo.int/search/en/result.jsf?inchikey=IEAKXXNRGSLYQ-DEOSSOPVSA-N>

► [PATENTSCOPE \(WIPO\)](#)

11.3 FDA Orange Book Patents



20 items

Download

Search

SORT BY

US Patent - A to Z

US Patent	Trade Name	Application Number	Applicant
12128033	CRENESSITY	218808	NEUROCRINE BIOSCIENCES INC
12128033	CRENESSITY	218808	NEUROCRINE BIOSCIENCES INC
12128033	CRENESSITY	218808	NEUROCRINE BIOSCIENCES INC
12128033	CRENESSITY	218820	NEUROCRINE BIOSCIENCES INC
10905690	CRENESSITY	218808	NEUROCRINE BIOSCIENCES INC

<< First < Previous Page 1 of 4 Next > Last >>

► [FDA Orange Book](#)

11.4 Chemical Co-Occurrences in Patents



Showing 3 of 100 View More Co-Occurrence and Evidence Data ↗		Download ↓
Chemical	Selected evidence	
 R121919 CID 9821250	11 patents from 6 patent families View All ↗ Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06 Treatment of congenital adrenal hyperplasia US-10905690-B2; Grant Date: 2021-02-02 Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms US-10837062-B2; Grant Date: 2020-11-17	
 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-pentan-3-ylpyrazolo[1,5-a]pyrimidin-7-amine CID 9884878	7 patents from 4 patent families View All ↗ Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06 Treatment of congenital adrenal hyperplasia US-11311544-B2; Grant Date: 2022-04-26 Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms US-10837062-B2; Grant Date: 2020-11-17	
 Antalarmin CID 177990	8 patents from 4 patent families View All ↗ Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06 Treatment of congenital adrenal hyperplasia US-10905690-B2; Grant Date: 2021-02-02 Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms US-10837062-B2; Grant Date: 2020-11-17	

► PubChem

11.5 Chemical-Disease Co-Occurrences in Patents



Showing 3 of 100 View More Co-Occurrence and Evidence Data ↗		Download ↓
Disease	Selected evidence	
Tauopathies	1 patent from 1 patent family View All ↗ Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06	
Amyloidosis	1 patent from 1 patent family View All ↗ Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06	
Pantothenate Kinase-Associated Neurodegeneration	1 patent from 1 patent family View All ↗ Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06	

► PubChem

11.6 Chemical-Gene Co-Occurrences in Patents



Showing 3 of 56 View More Co-Occurrence and Evidence Data ↗		Download ↓
Gene	Selected evidence	
crh	<p>9 patents from 7 patent families View All ↗</p> <p>Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06</p> <p>Method for predicting a treatment response to a CRHR1 antagonist and/or a VIB antagonist in a patient with depressive and/or anxiety symptoms US-10190168-B2; Grant Date: 2019-01-29</p> <p>Aminothiazole derivatives and their use as CRF receptor ligands US-6586456-B1; Grant Date: 2003-07-01</p>	
crhr2	<p>2 patents from 2 patent families View All ↗</p> <p>Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06</p> <p>VIB receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level US-10857129-B2; Grant Date: 2020-12-08</p>	
insr	<p>1 patent from 1 patent family View All ↗</p> <p>Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06</p>	

► PubChem

11.7 Chemical-Organism Co-Occurrences in Patents



Showing 3 of 46 View More Co-Occurrence and Evidence Data ↗		Download ↓
Organism	Selected evidence	
chichester	<p>1 patent from 1 patent family View All ↗</p> <p>Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06</p>	
armoracia rusticana (horseradish)	<p>1 patent from 1 patent family View All ↗</p> <p>Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06</p>	
anura (frogs & toads)	<p>1 patent from 1 patent family View All ↗</p> <p>Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling EP-2522351-B1; Grant Date: 2017-09-06</p>	

► PubChem

12 Interactions and Pathways



12.1 Chemical-Target Interactions



6 items Download					
Search			SORT BY Data Source - A to Z		
Protein	Gene	Taxonomy	Action	Evidence	Data Source
	CRHR1	Homo sapiens (human)	Inhibitor		Drug Gene Interaction database (DGIdb)
Corticotropin-releasing factor receptor 1	CRHR1	Homo sapiens (human)	Antagonist	PMID:11907190	IUPHAR/BPS Guide to PHARMACOLOGY
	ALAS2	Homo sapiens (human)	Inhibitor		Drug Gene Interaction database (DGIdb)
	CRHR1	Homo sapiens (human)	4-(2-chloro-4-methoxy-5-methylphenyl)-N(2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine binds to and results in decreased activity of CRHR1 protein	PMID:21618986 PMID:23294766	Comparative Toxicogenomics Database (CTD)
Corticotropin-releasing factor receptor 1	CRHR1	Homo sapiens (human)	Corticotropin releasing factor receptor 1 antagonist	PMID:11907190 25446760	ChEMBL

[First](#)
[Previous](#)
Page 1 of 2
[Next](#)
[Last](#)

[ChEMBL](#); [Comparative Toxicogenomics Database \(CTD\)](#); [Drug Gene Interaction database \(DGIdb\)](#); [IUPHAR/BPS ...](#)

13 Biological Test Results



13.1 BioAssay Results



92 items Download	
Search	
SORT BY Activity Value - Increasing	
Binding affinity towards human Corticotropin releasing factor receptor 1 by the displacement of [125I]CRF from CHO cells Activity Outcome: Active Activity Type: Ki Activity Value: 0.240000 µM BioAssay AID: 53966 Target Name: CRHR1 - corticotropin releasing hormone receptor 1 (human) Substance SID: 103258755 Compound CID: 5282340	
Binding affinity towards human Corticotropin releasing factor receptor 1 by the displacement of [125I]CRF from CHO cells Activity Outcome: Active Activity Type: Ki Activity Value: 0.240000 µM BioAssay AID: 53966 Target Name: LINC02210-CRHR1 - LINC02210-CRHR1 readthrough (human) Substance SID: 103258755 Compound CID: 5282340	
Viability qHTS for spleen associated tyrosine kinase inhibitor (SYKi) drug resistant MV4-11 cells Activity Outcome: Active Activity Type: Potency Activity Value: 0.819900 µM BioAssay AID: 1963824 Target Name: SYK - spleen associated tyrosine kinase (human) Substance SID: 363680369 Compound CID: 5282340	
Viability qHTS for spleen associated tyrosine kinase inhibitor (SYKi) drug resistant MV4-11 cells Activity Outcome: Active Activity Type: Potency Activity Value: 0.819900 µM BioAssay AID: 1963824 Target Name: Tyrosine-protein kinase SYK (human)	

Substance SID: [363680369](#) Compound CID: [5282340](#)[Primary qHTS to identify gynecologic anti-cancer compounds using libraries of approved drugs and bioactive compounds](#)Activity Outcome: [Unspecified](#) Activity Value: 1.000000 µMBioAssay AID: [1345084](#)Substance SID: [363680369](#) Compound CID: [5282340](#)[«](#) [First](#) [«](#) [Previous](#) Page [1](#) of 19 [Next](#) [»](#) [Last](#) [»](#)[► PubChem](#)

14 Classification



14.1 MeSH Tree



1 item

[View in Classification Browser](#) [MeSH Tree](#) > [Chemicals and Drugs Category](#) > [Heterocyclic Compounds](#) > [Heterocyclic Compounds, 1-Ring](#) > [Azoles](#) > [Thiazoles](#)[⌵ Show alternative paths](#)[crinecerfont](#)MeSH Concept: [M000758004](#)MeSH Descriptor: [C000723083](#)[► Medical Subject Headings \(MeSH\)](#)

14.2 NCI Thesaurus Tree



1 item

[View in Classification Browser](#) [NCI Thesaurus](#) > [Drug, Food, Chemical or Biomedical Material](#) > [Pharmacologic Substance](#) > [Hormone Therapy Agent](#) > [Hormone Antagonist](#)[Crinecerfont](#)[► NCI Thesaurus \(NCIt\)](#)

14.3 ChEBI Ontology



1 item

[View in Classification Browser](#) [ChEBI Ontology](#) > [chemical entity](#) > [molecular entity](#) > [main group molecular entity](#) > [p-block molecular entity](#) > [carbon group molecular entity](#) > [organic molecular entity](#) > [organic amino compound](#) > [amine](#)[⌵ Show alternative paths](#)[SSR 125543](#)[► ChEBI](#)

14.4 KEGG: USP



1 item

[View in Classification Browser](#) [USP drug classification](#) > [Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment](#) > [Crinecerfont](#)[Crinecerfont \(USAN\)](#)[► KEGG](#)

14.5 KEGG: Target-based Classification of Drugs



1 item

View in Classification Browser

Target-based classification of drugs > G Protein-coupled receptors > Secretin receptor family > Corticotropin-releasing hormone > CRHR1 [HSA:1394] [KO:K04578]

Crinecerfont (USAN)

► [KEGG](#)

14.6 FDA Pharm Classes



2 items

View in Classification Browser

FDA Pharmacological Classification > [MoA] Mechanisms of Action

Corticotropin-releasing Factor Type 1 Receptor Antagonists [MoA]

FDA Pharmacological Classification > [EPC] Established Pharmacologic Class

Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]

► [FDA Pharm Classes](#)

14.7 ChemIDplus



12 items

View in Classification Browser

ChemIDplus Chemical Information Classification > Other Resources (Internet Locators)

CTD

Comparative Toxicogenomics Database - CTD selects and organizes gene, sequence, chemical, reference, and taxonomic data about gene-chemical interactions. It is hosted at North Carolina State University (NCSTU).

ChemIDplus Chemical Information Classification > Other Resources (Internet Locators)

ChEBI

Chemical Entities of Biological Interest - Dictionary of molecular entities focused on "small" chemical compounds. ChEBI is part of the EMBL-European Bioinformatics Institute.

ChemIDplus Chemical Information Classification > NLM Resources (File Locators)

ClinicalTrials.gov

ClinicalTrials.gov - ClinicalTrials.gov offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions

ChemIDplus Chemical Information Classification > NLM Resources (File Locators)

DrugPortal

Drug Information Portal - Portal to selected drug information from the U.S. National Library of Medicine and other key U.S. Government agencies

ChemIDplus Chemical Information Classification > Other Resources (Internet Locators)

EPA CompTox

« First < Previous Page 1 of 3 Next > Last »

► [ChemIDplus](#)

14.8 IUPHAR / BPS Guide to PHARMACOLOGY Target Classification



1 item View in Classification Browser

Guide to Pharmacology Target Classification > Receptors > G protein-coupled receptors

Corticotropin-releasing factor receptors

Corticotropin-releasing factor (CRF, **nomenclature as agreed by the NC-IUPHAR subcommittee on Corticotropin-releasing Factor Receptors**) receptors are activated by the endogenous peptides corticotrophin-releasing hormone, a 41 amino-acid peptide, urocortin 1, 40 amino-acids, urocortin 2, 38 amino-acids and urocortin 3, 38 amino-acids. CRF₁ and CRF₂ receptors are activated non-selectively by CRH and UCN. CRF₂ receptors are selectively activated by UCN2 and UCN3. Binding to CRF receptors can be conducted using radioligands [¹²⁵I]Tyr⁰-CRF or [¹²⁵I]Tyr⁰-sauvagine with K_d values of 0.1-0.4 nM. CRF₁ and CRF₂ receptors are non-selectively antagonized by α-helical CRF, D-Phe-CRF-(12-41) and astressin. CRF₁ receptors are selectively antagonized by small molecules NBI27914, R121919, antalarmin, CP 154,526, CP 376,395. CRF₂ receptors are selectively antagonized by antisauvagine and astressin 2B. Although selective small molecule CRF₁ receptor antagonists were not effective in treating major depressive disorder, posttraumatic stress disorder, or alcohol use disorder in clinical trials, recent phase 2 studies have found that CRF₁ receptor antagonists effectively reduce adrenocortical androgens and precursors in congenital adrenal hyperplasia.

▶ IUPHAR/BPS Guide to PHARMACOLOGY

14.9 ChEMBL Target Tree



1 item View in Classification Browser

ChEMBL Protein Target Tree > Membrane receptor > Family B G protein-coupled receptor > Peptide receptor (family B GPCR) > Corticotropin releasing factor receptor

Corticotropin releasing factor receptor

Cell surface proteins that bind corticotropin-releasing hormone with high affinity and trigger intracellular changes which influence the behavior of cells. The corticotropin releasing-hormone receptors on anterior pituitary cells mediate the stimulation of corticotropin release by hypothalamic corticotropin releasing factor. The physiological consequence of activating corticotropin-releasing hormone receptors on central neurons is not well understood. [MESH:D018019]

▶ ChEMBL

14.10 EPA DSSTox Classification



5 items View in Classification Browser

CompTox Chemicals Dashboard Chemical Lists > LIST

⌵ Show alternative paths

[\[CPDAT\] Navigation Panel to CPDat Versioned Structure Lists](#)

Short_Description: CPDat Structure lists are versioned iteratively and this panel navigates between the various versions

CompTox Chemicals Dashboard Chemical Lists > LIST

⌵ Show alternative paths

[\[FDAUNII0421\] LIST: FDA UNII List April 12th 2021 Download](#)

Short_Description: FDA's Global Substance Registration System Unique Ingredient Identifiers (UNII)s file: April 12th 2021 download subset of chemicals with CASRN and/or structure SMILES

CompTox Chemicals Dashboard Chemical Lists > MISCELLANEOUS

⌵ Show alternative paths

[\[CPDATv2\] Chemical and Products Database v2](#)

Short_Description: Chemicals contained in the EPA's Chemical and Products Database: Version 2 (last updated March 13th 2024)

CompTox Chemicals Dashboard Chemical Lists > MISCELLANEOUS

⌵ Show alternative paths

[\[CPDATv3\] Chemical and Products Database v3](#)

Short_Description: Chemicals contained in the EPA's Chemical and Products Database: Version 3 (last updated November 1st 2024)

CompTox Chemicals Dashboard Chemical Lists > MISCELLANEOUS

⌵ Show alternative paths

[\[CPDATv4.1\] Chemical and Products Database v4](#)

Short_Description: Chemicals contained in the EPA's Chemical and Products Database: Version 4.1 (last updated June 5th 2025)

▶ EPA DSSTox

14.11 FDA Drug Type and Pharmacologic Classification



1 item

View in Classification Browser

FDA Drug Type and Pharmacologic Classification > Drug Type

HUMAN PRESCRIPTION DRUG

▶ [National Drug Code \(NDC\) Directory](#)

14.12 PFAS and Fluorinated Organic Compounds in PubChem



1 item

View in Classification Browser

PFAS and Fluorinated Compounds in PubChem > Organofluorine compounds > Fluorinated aromatic substances > Fluorinated aromatic ring(s) with non-fluorinated aliphatic side chain(s) > Contains 01 Fluorine atom

Exact mass range 250-500

Cases where the chemical structure exact mass is in the range of 250-500 Daltons

▶ [PubChem](#)

14.13 MolGenie Organic Chemistry Ontology



39 items

View in Classification Browser

MolGenie Organic Chemistry Ontology > ChEBI chemical entities > substructural concepts > functional groups > oxygen containing functional groups > ethers

aryl alkyl ethers

MolGenie Organic Chemistry Ontology > ChEBI chemical entities > substructural concepts > scaffolds > simple organic compound scaffolds

biaryls

MolGenie Organic Chemistry Ontology > ChEBI chemical entities > substructural concepts > scaffolds > simple organic compound scaffolds > benzene derivatives > alkyl benzene derivatives > methylbenzenes

toluenes

Any member of the class of benzenes that is a substituted benzene in which the substituents include one (and only one) methyl group.
 ChEBI: [27024](#)
 MeSH: [D014050](#)

MolGenie Organic Chemistry Ontology > ChEBI chemical entities > substructural concepts > scaffolds > ring systems > plain ring systems > 1-membered ring systems > ring size 3

cyclopropanes

MolGenie Organic Chemistry Ontology > ChEBI chemical entities > calculated properties

lipophilic compounds

Using a Fragment Based LogP from OpenChemLib > 5.

<< First < Previous Page 1 of 8 Next > Last >>

▶ [MolGenie](#)

14.14 Chemicals in PubChem from Regulatory Sources



3 items

View in Classification Browser

Chemicals in PubChem from Regulatory Sources > US FDA > FDA Human Drugs > Drugs@FDA

Active ingredients

Active ingredient list for FDA approved drugs.

Chemicals in PubChem from Regulatory Sources > US FDA > FDA Human Drugs > Drugs@FDA

Prescription drugs

Prescription drugs in the FDA approved drug dataset.

Chemicals in PubChem from Regulatory Sources > EU EMA

Paediatric drugs and substances

Drug and substance information from paediatric investigation plans

► PubChem

14.15 Open Targets Classification



3 items

View in Classification Browser

Disease Classification > nervous system disease > central nervous system disease > brain disease > mental or behavioural disorder

⌵ Show alternative paths

anxiety disorder

A category of psychiatric disorders which are characterized by anxious feelings or fear often accompanied by physical symptoms associated with anxiety.

Disease Classification > nervous system disease > central nervous system disease > brain disease > mental or behavioural disorder > mood disorder

⌵ Show alternative paths

depressive disorder

A melancholy feeling of sadness and despair.

Disease Classification > endocrine system disease > adrenal gland disease > adrenogenital syndrome

⌵ Show alternative paths

congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is an inherited endocrine disorder caused by a steroidogenic enzyme deficiency that is characterized by adrenal insufficiency and variable degrees of hyper or hypo androgyny manifestations, depending of the type and the severity of the disease.

► Open Targets

15 Information Sources



FILTER BY SOURCE

ALL SOURCES

1. CAS Common Chemistry

LICENSE

The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.
<https://creativecommons.org/licenses/by-nc/4.0/>

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-((1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-N-2-propyn-1-yl-2-thiazolamine

https://commonchemistry.cas.org/detail?cas_rn=752253-39-7

2. ChemIDplus

LICENSE

<https://www.nlm.nih.gov/copyright.html>

SSR 125543

<https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0752253397>

ChemIDplus Chemical Information Classification
<https://pubchem.ncbi.nlm.nih.gov/source/chemidplus>

3. DrugBank

LICENSE
 Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/legalcode>)
https://www.drugbank.ca/legal/terms_of_use

Crinecerfont
<https://www.drugbank.ca/drugs/DB18518>

4. EPA DSSTox

LICENSE
<https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources>

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-N-(prop-2-yn-1-yl)-1,3-thiazol-2-amine]
<https://comptox.epa.gov/dashboard/DTXSID10996687>
 CompTox Chemicals Dashboard Chemical Lists
<https://comptox.epa.gov/dashboard/chemical-lists/>

5. FDA Global Substance Registration System (GSRS)

LICENSE
 Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
<https://www.fda.gov/about-fda/about-website/website-policies#linking>

Crinecerfont
<https://gsrs.ncats.nih.gov/ginas/app/beta/substances/MFT24BX55I>

6. ChEBI

SSR 125543
<https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:34969>
 ChEBI Ontology
<https://www.ebi.ac.uk/chebi/>

7. FDA Pharm Classes

LICENSE
 Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.
<https://www.fda.gov/about-fda/about-website/website-policies#linking>

CRINECERFONT
<https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm>
 FDA Pharmacological Classification
<https://www.fda.gov/industry/structured-product-labeling-resources/pharmacologic-class>

8. LiverTox

LICENSE
<https://www.nlm.nih.gov/copyright.html>

Crinecerfont
<https://www.ncbi.nlm.nih.gov/books/n/livertox/Crinecerfont/>

9. ChEMBL

LICENSE
 Access to the web interface of ChEMBL is made under the EBI's Terms of Use (<http://www.ebi.ac.uk/Information/termsofuse.html>). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (<http://creativecommons.org/licenses/by-sa/3.0/>).
<http://www.ebi.ac.uk/Information/termsofuse.html>

CHEMBL1628268
<https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1628268>
 CRINECERFONT
<https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL291657>
 ChEMBL Protein Target Tree
<https://www.ebi.ac.uk/chembl/g/#browse/targets>

10. Open Targets

LICENSE
 Datasets generated by the Open Targets Platform are freely available for download.
<https://platform-docs.opentargets.org/licence>

CRINECERFONT
<https://platform.opentargets.org/drug/CHEMBL291657>
 Disease Classification
https://platform.opentargets.org/downloads/clinical_target/access

11. **Comparative Toxicogenomics Database (CTD)****LICENSE**

It is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.

<http://ctdbase.org/about/legal.jsp>

4-(2-chloro-4-methoxy-5-methylphenyl)-N((2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl)-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine

<https://ctdbase.org/detail.go?type=chem&acc=C451725>

12. **Drug Gene Interaction database (DGIdb)****LICENSE**

The data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.

<http://www.dgldb.org/downloads>

CRINECERFONT

<https://www.dgldb.org/drugs/ncit:C74708>

SSR125543A

<https://www.dgldb.org/drugs/iuphar.ligand:3533>

13. **IUPHAR/BPS Guide to PHARMACOLOGY****LICENSE**

The Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL)

<https://opendatacommons.org/licenses/odbl/>. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0

International License (<http://creativecommons.org/licenses/by-sa/4.0/>)

<https://www.guidetopharmacology.org/about.jsp#license>

crinecerfont

<https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3533>

Guide to Pharmacology Target Classification

<https://www.guidetopharmacology.org/targets.jsp>

14. **Therapeutic Target Database (TTD)**

SSR125543

<https://ttd.idrblab.cn/data/drug/details/D0511N>

15. **ClinicalTrials.gov****LICENSE**

The ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.

<https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use>

<https://clinicaltrials.gov/>

16. **Drugs and Lactation Database (LactMed)****LICENSE**

<https://www.nlm.nih.gov/copyright.html>

Crinecerfont

<https://www.ncbi.nlm.nih.gov/books/n/lactmed/crinecerfont/>

17. **Drugs@FDA****LICENSE**

Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.

<https://www.fda.gov/about-fda/about-website/website-policies#linking>

CRINECERFONT

<https://www.accessdata.fda.gov/scripts/cder/daf/>

18. **FDA Orange Book****LICENSE**

Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.

<https://www.fda.gov/about-fda/about-website/website-policies#linking>

4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-((1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL)-5-METHYL-N-2-PROPYN-1-YL-2-THIAZOLAMINE

<https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book>

19. **EU Clinical Trials Register**

<https://www.clinicaltrialsregister.eu/>

20. **European Medicines Agency (EMA)****LICENSE**

Information on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.

<https://www.ema.europa.eu/en/about-us/about-website/legal-notice>

4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-((1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL)-5-METHYL-N-2-PROPYN-1-YL-2-THIAZOLAMINE
<https://www.ema.europa.eu/en/homepage>

21. Japan Chemical Substance Dictionary (Nikkaji)

http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J2.788.046K

22. KEGG

LICENSE

Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license
<https://www.kegg.jp/kegg/legal.html>

<https://www.kegg.jp/entry/D12366>

USP drug classification

http://www.genome.jp/kegg-bin/get_htext?br08302.keg

Target-based classification of drugs

http://www.genome.jp/kegg-bin/get_htext?br08310.keg

23. National Drug Code (NDC) Directory

LICENSE

Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.

<https://www.fda.gov/about-fda/about-website/policies#linking>

4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-((1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL)-5-METHYL-N-2-PROPYN-1-YL-2-THIAZOLAMINE

<https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory>

24. NCI Thesaurus (NCIt)

LICENSE

Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.

<https://www.cancer.gov/policies/copyright-reuse>

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ncit=ncit&code=C174708

NCI Thesaurus

<https://ncit.nci.nih.gov>

25. NLM RxNorm Terminology

LICENSE

The RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.

<https://www.nlm.nih.gov/research/umls/rxnorm/docs/termservice.html>

crinecerfont

<https://rxnav.nlm.nih.gov/id/rxnorm/2701386>

26. Pharos

LICENSE

Data accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.

<https://pharos.nih.gov/about>

SSR125543A

<https://pharos.nih.gov/ligands/W3JY8TJURTS>

27. Springer Nature

<https://pubchem.ncbi.nlm.nih.gov/substance/341196272>

28. Thieme Chemistry

LICENSE

The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.

<https://creativecommons.org/licenses/by-nc-nd/4.0/>

<https://pubchem.ncbi.nlm.nih.gov/substance/523047658>

29. Wikidata

LICENSE

CCZero

<https://creativecommons.org/publicdomain/zero/1.0/>

<https://www.wikidata.org/wiki/Q27088874>

30. Wikipedia

Crinecerfont

<https://en.wikipedia.org/wiki/Crinecerfont>

31. PubChem

<https://pubchem.ncbi.nlm.nih.gov>

PFAS and Fluorinated Compounds in PubChem

https://gitlab.com/uniluxembourg/lcsb/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf

Chemicals in PubChem from Regulatory Sources

32. Medical Subject Headings (MeSH)

LICENSE

Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.

<https://www.nlm.nih.gov/copyright.html>

crinecerfont

<https://id.nlm.nih.gov/mesh/M000758004.html>

MeSH Tree

<https://www.nlm.nih.gov/mesh/meshhome.html>

33. MolGenie

LICENSE

CC-BY 4.0

<https://creativecommons.org/licenses/by/4.0/>

MolGenie Organic Chemistry Ontology

<https://github.com/MolGenie/ontology/>

34. PATENTSCOPE (WIPO)

SID 389857487

<https://pubchem.ncbi.nlm.nih.gov/substance/389857487>

35. NCBI

<https://www.ncbi.nlm.nih.gov/projects/linkout>

Connect with NLM



National Library of Medicine
8600 Rockville Pike, Bethesda, MD
20894

Web Policies
FOIA
HHS Vulnerability Disclosure

Help
Accessibility
Careers

NLM | NIH | HHS | USA.gov